Oppenheimer analyst Andreas Argyrides initiated coverage of ProQR Therapeutics (PRQR) with an Outperform rating and $15 price target The firm says the Axiomer RNA editing platform leads the next wave of genomics medicine by offering a precise, reversible alternative to DNA-based therapies. With first-in-human competitor data in October validating RNA-editing, ProQR is poised to further capitalize on its “differentiated” development strategy focusing on diseases with genetically known protective mutations, the analyst tells investors in a research note. Opco expects multiple catalysts this year from competitors and ProQR.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRQR:
- ProQR Therapeutics Advances Axiomer RNA-Editing Platform with Strategic Partnerships
- ProQR Secures $8.1 Million for Rett Syndrome RNA Therapy
- ProQR Therapeutics announces $8.1M in new funding from RSRT
- ProQR Strengthens RNA Editing Team with Key Appointment
- ProQR Therapeutics appoints Beal as Chief ADAR Scientist